Day 1

Sunday 21 May

OPENING CEREMONY
  • Welcome addresses
  • Awards Ceremony
  • Opening Lecture
    Forgiveness for Individual, Family, and Community Well-Being
    R. Enright (USA)

Day 2

Monday 22 May

  • 9:00 – 11:00 EFLM SYMPOSIUM
    Inappropriate use of laboratory resources – Demand management tools and how to use them – Session chairs: J. Cadamuro (Austria), M. Salinas (Spain)
    Definition and magnitude of over-and underuse – J. Cadamuro (Austria)
    Tools to overcome inappropriate test ordering – A.M. Simundic (Croatia)
    Examples of successful interventions – M. Salinas (Spain)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 IFCC SYMPOSIUM
    Artificial intelligence applications in clinical laboratory medicine – Session chair: D. Gruson (Belgium)
    Artificial intelligence: current and future applications in laboratory medicine – D. Gruson (Belgium)
    Artificial intelligence to drive prevention and improve patient outcomes – Speaker to be announced
    The value of AI in the mobile health ecosystem – N. Delvaux (Belgium)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 IFCC SYMPOSIUM
    Precision Medicine will boost Medical Test Standardization of Protein Biomarkers – Session chairs: C. Cobbaert (Netherlands), P. Gillery (France)
    Critical Appraisal of IFCC SD standardization/harmonization efforts: making up the balance – P. Gillery (France)
    Embracing (patho-)physiological diversity at the molecular level: unraveling the human blood proteome – N. Kelleher (USA)
    Promising (glyco-) and proteoform measuring technologies to accurately quantify the measurand of interest: what is in the pipeline? – Y. van der Burgt (Netherlands)
    Bottom-up proteomics enables peptide-based calibration of molecular defined proteins for realizing SI-traceability of test results – C. Cobbaert (Netherlands)
  • 9:00 – 11:00 SYMPOSIUM 1
    MicroRNA: from detection technologies to applications – Session chair: V. Taly (France)
    Diagnostic potentials of circulating EV/EXO-related biomarker signatures – M. W. Pfaff l (Germany)
    Droplet-based microfluidics for miRNA detection – V. Taly (France)
    miRNA profiling in cells and extra-cellular vesicles using high-throughput sequencing in human diseases and disease models – J. Tost (France)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11.00 EFLM SYMPOSIUM
    Precision Medicine – Session chair: T. Ozben (Turkey)
    Multi-omics profiling in the era of cancer Precision Medicine – T. Ozben (Turkey)
    Genetic diagnosis and multi-omics clustering for diabetes precision medicine – P. Froguel (UK)
    Computer-assisted integration of multi-dimensional patient’s data for poly-therapies management – M. Simmaco (Italy)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 SIBioC SYMPOSIUM
    Opportunities and challenges for digital morphology in Hematology – Session Chairs: S. Buoro (Italy), G. Da Rin (Italy)
    From the digital microscope to artificial intelligence – G. D’Onofrio (Italy)
    The virtual slide in hematology – G. Zini (Italy)
    Digital morphology analyzers in hematology: a disruptive innovation? The experience of SIBioC hematology study group – M. Seghezzi (Italy)
    Two oral communications selected among participants’ abstracts
  • 11:30 – 12:30 PLENARY LECTURE
    Digital health, big data and smart technologies for the care of patients with cancer – N. Waddel (Australia)
  • 14:30 – 16:30IFCC SYMPOSIUM
    Central Role of the Clinical Laboratory in Public Health & Patient Care Continuum – Session chairs: R. Erasmus (South Africa), A. St John (Australia)
    Critical review of the evidence supporting the value of laboratory medicine in clinical care – K. Adeli (Canada)
    Anatomy of a value proposition for laboratory medicine – A. St John (Australia)
    Demonstrating the value of laboratory medicine from an industry perspective – B. Meyer (UK)
    Strategies for Promoting the Value of Laboratory Medicine in North America – D. Kinniburgh (Canada)
  • 12:30 – 14:00 POSTER SESSION
  • 14:30 – 15:30 MEET THE EXPERT
    Infrared spectroscopy – S. De Bruyne (Belgium)
  • 15:45 – 16:45 DEBATE
    The use of cardiac biomarkers in risk stratification – F. Apple (USA), N. Mills (UK)

Day 3

Tuesday 23 May

  • 9:00 – 11:00 SYMPOSIUM 2
    COVID-19 diagnosis, therapy and outcome – Session chair: M. Ciccozzi (Italy)
    SARS-CoV-2: Epidemiological and genomic analysis – L.B. Snell (UK)
    Challenges in COVID-19 testing strategies – P. M Bossuyt (Netherlands)
    Severe COVID-19: is it a viral or an immunological disease? – A. Guillon (France)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 SYMPOSIUM 3
    Diagnostic Challenges in Sepsis – Session chair: C. Tsatsanis (Greece)
    Immunology of sepsis: diagnostic and therapeutic opportunities – T. Van der Poll (Netherlands)
    Harmonisation of Procalcitonin as a sepsis biomarker: problems and solutions – V. Delatour (France)
    Functional biomarkers of Sepsis Immunosuppression – C. Tsatsanis (Greece)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 SYMPOSIUM 4
    Towards the next generation of Laboratory Information Systems – Session chair: V. Lukić (Serbia)
    LIS 2.0: what does the future hold? – V. Lukić (Serbia)
    Are laboratory information systems prepared for interconnected health care? – A. Bietenbeck (Germany)
    An evaluation framework for effective and safe laboratory information systems – M. Yusof (Malaysia)
    Two oral communications selected among participants’ abstracts
  • 9.00-11.00 SYMPOSIUM 5
    Autoimmune diseases – Session chairs: D. Barnali (India), J. Sheldon (UK)
    IgG4 related disease – E. Della Torre (Italy)
    The role of complement in autoimmune disease – J. Thurman (USA) Harmonisation of Autoimmune Testing – J. Sheldon (UK)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 IFCC SYMPOSIUM
    Advancing Excellence in Laboratory Medicine Worldwide: An Update from IFCC
    Taskforces – Session chairs: K. Adeli (Canada), A. Haliassos (Greece)
    Enhancing Laboratory Quality on a Global Level: Results of the IFCC EQA Pilot Study – E. Amann (Germany)
    Closing the Gaps in Newborn Screening: The IFCC Global NBS Program – J. Bonham (UK)
    Impact of the Clinical Laboratory in Clinical Medicine: Developing the Evidence – Z. Zhan (USA)
    Global Database of Adult and Pediatric Reference Intervals – J. Zierk (Germany)
  • 9:00 – 11:00 SIBIOC SYMPOSIUM
    The challenge of harmonization in laboratory medicine – Session chairs: A. Carobene (Italy), F. Ceriotti (Italy)
    Harmonization of the Pre-analytical phase – A-M. Simundic (Croatia)
    Harmonization of the Analytical phase – M. Panteghini (Italy)
    Harmonization of the Post-analytical phase – M. Plebani (Italy)
    Two oral communications selected among participants’ abstracts
  • 11:30 – 12:30 PLENARY LECTURE
    Viral Evolution and Host Immune ResponsesA. Fischer (France)
  • 14:30 – 16:30 EFLM SYMPOSIUM
    Quality in clinical laboratory: a moving target
    Evaluation and monitoring of analytical quality – M. Panteghini (Italy)
    Quality indicators in the total testing process – V. De Guire (Canada)
    Outcome measurement and integration of quality measures in laboratory medicine – M. Plebani (Italy)
    Two oral communications selected among participants’ abstracts
  • 12:30 – 14:00 POSTER SESSION
  • 14:30 – 15:30 PREANALYTICAL CASES
    Preanalytical mysteriesS. Jovičić (Serbia), J. Cadamuro (Austria)
  • 15:45 – 16:45 CLINICAL CASES
    Bone turnover markers + vitamin DE. Cavallier (Belgium), M. Hermann (Germany)

Day 4

Wednesday 24 May

  • 9:00 – 11:00 SYMPOSIUM 6
    Preanalytical phase and patient outcome – Session chair: A.M. Simundic (Croatia)
    How to measure patient related outcomes & cost of preanalytical errors? – G. Lippi (Italy)
    New venous catheter blood draw device and its impact on patient and laboratory related outcomes – K. Doyle (USA)
    Over-estimation of plasma glucose in collection tubes containing citrate stabilizer – C.M. Florkowski (New Zealand)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 SYMPOSIUM 7
    Young Scientist Session – Session chairs: K. Taha Ucar (Turkey), B. Das (India)
    Circulating cancer biomarkers: where are we now? – A. Tikhonov (Russia)
    Immature platelet fraction as an early inflammatory biomarker – C. Imperiali (Spain)
    Dialogue between lab and clinicians for a win-win collaboration – M. Lenski (France)
    Laboratory Critical Results management – S. Fares Taie (Argentina)
  • 9:00 – 11:00 SYMPOSIUM 8
    Bone as an endocrine organ – Session chair: E. Cavalier (Belgium)
    Relation between bone and energy metabolisms – C. Confavreux (France)
    Sclerostin: from pathophysiology to laboratory determination – R. N. Jørgensen (Denmark)
    FGF23: clinical and laboratory perspectives – A. Heijboer (Netherlands)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 SYMPOSIUM 9
    Translating biomarkers from research to clinical use in traumatic brain injury – Session chairs: K. Makris (Greece), J. Montaner (Spain)
    Pathophysiology and epidemiology of traumatic brain injury – J. Montaner (Spain)
    Biomarkers of traumatic brain injury: current state and unresolved issues – H. Zettenberg (Sweden)
    Current trends in discovery of new TBI biomarkers – J. C. Sanchez (Switzerland)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 SIBioC SYMPOSIUM
    The latest advances in diabetes clinical and laboratory research – Session chairs: A. Mosca (Italy), A. Terreni (Italy)
    Nature of diabetes: time for a rethink? – D. Leslie (UK)
    Diabetic kidney disease: new clinical and therapeutic issues – G. Pugliese (Italy)
    Role of glycated albumin for diagnosis and management of diabetes mellitus – E. Selvin (USA)
    Two oral communications selected among participants’ abstracts
  • 12:30 – 14:00 POSTER SESSION
  • 14:30 – 15:30 CLINICAL CASES
    Challenges in the interpretation of laboratory tests in hemostasisE. Favaloro (Australia)
  • 15:45 – 16:45 CLINICAL CASES
    Clinical cases: Neuroimmune diseases – Session Chair: J.A. Goodfellow (UK)
    “Brain on Fire”: Neuroimmunology Case Study Based Discussion – B. Das (India)
    Technical laboratory and clinical challenges and opportunities around autoantibody testing in Neuroimmunology – J.A. Goodfellow (UK)
  • 11:30 – 12:30 PLENARY LECTURE
    Multi-Omics for Biomarker Discovery: the Value of NMR-SpectroscopyM. Nauck (Germany)

Day 5

Thursday 25 May

  • 9:00 – 11:00 SYMPOSIUM 10
    Biomarkers of liver diseases
    Do we need separate non-invasive test to assess nonalcoholic steatohepatitis for patients with and without Human Immunodeficiency Virus? – M. Lemoine (UK)
    What combination of non-invasive fibrosis tests should be used for the diagnosis of fibrosis in NAFLD / MAFLD? – J. Boursoer (France)
    Adipocytokines and liver diseases in 2023: where are we? – C. Peralta (Spain)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 SYMPOSIUM 11
    The role of clinical laboratory in kidney transplantation – Session chairs: J. P. Cristol (France), A. Djamali (USA)
    Non-invasive biomarkers of kidney allograft injury: role of multimodality testing – A. Djamali (USA)
    Immunosuppressive drug Monitoring for a Personalized Therapy – P. Marquet (France)
    Kidney functions after transplantation: more than glomerular filtration rate – J. P. Cristol (France)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 SYMPOSIUM 12
    Sources of interference in laboratory testing – Session chair: G. Dimeski (Australia)
    Biotin interference in laboratory testing – P. B. Kyle (USA)
    Troponin Interferences with current generation assays – G. Dimeski (Australia)
    Interferences in Immunoassays – K. Ghazal (France)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 SYMPOSIUM 13
    Prenatal testing – Session chair: K. Spencer (UK)
    First trimester Fetal Chromosomal Anomaly Screening – K. Spencer (UK)
    EQA in prenatal testing and PAPP-A standardisation – C. Sturgeon (UK)
    Risk assessment for pre-eclamsia throughout pregnancy – L. Poon (Hong Kong)
    Two oral communications selected among participants’ abstracts
  • 9:00 – 11:00 SIBioC SYMPOSIUM
    Diagnostic workup of monoclonal gammopathies – Session chairs: M. Mussap (Italy), G. Palladini (Italy)
    Advances in monitoring and treatment of multiple myeloma – F. Gay (Italy)
    Differential diagnosis of MGCS – speaker to be determined
    Circulating tumor cells and minimal residual disease in multiple myeloma – B. Paiva (Spain)
    Two oral communications selected among participants’ abstracts
  • 11.30 – 12.30 PLENARY LECTURE
    Diagnostic advances in dementia – K. Blennow (Sweden)
  • 12.30 – 13.30 CLOSING CEREMONY
    Closing remarks
    IFCC President – K. Adeli
    EFLM President – T. Ozben
    SIBioC President – T. Trenti
    Farewell Party